Thyroid Inflammatory Myofibroblastic Tumor: A Rare Case, Literature Review  

作　　者：Hamza Sümter Hamza Sümter(Department of Internal Medicine, Hematology, Uak Training and Research Hospital, Uak, Trkiye)

机构地区：[1]Department of Internal Medicine, Hematology, Uak Training and Research Hospital, Uak, Trkiye

出　　处：《Open Journal of Internal Medicine》2024年第4期337-342,共6页内科学期刊(英文)

摘　　要：Inflammatory myofibroblastic tumor has been referred to by many different names in the past, such as plasma cell granuloma, inflammatory pseudotumor, fibrous histiocytoma, fibroxanthoma, xanthogranuloma. It was first described in the 1930s. It originates from soft tissue. It has low malignancy potential. It is rarely seen. While it is often localized in the lungs, it can rarely be localized in the thyroid gland. Its etiology and pathogenesis are unknown. Diagnosis is based on postoperative immunohistochemical evaluation. Although surgical resection is the main treatment method, there is no standard approach. Recurrence is not expected in general. However, cases of recurrence after a long period of time have also been reported. In this study, a 46-year-old female patient was presented with thyroid inflammatory myofibroblastic tumor that developed after COVID-19. Another notable point in the case is that her mother had myeloma with mutations (changes in chromosomes 11 and 14).Inflammatory myofibroblastic tumor has been referred to by many different names in the past, such as plasma cell granuloma, inflammatory pseudotumor, fibrous histiocytoma, fibroxanthoma, xanthogranuloma. It was first described in the 1930s. It originates from soft tissue. It has low malignancy potential. It is rarely seen. While it is often localized in the lungs, it can rarely be localized in the thyroid gland. Its etiology and pathogenesis are unknown. Diagnosis is based on postoperative immunohistochemical evaluation. Although surgical resection is the main treatment method, there is no standard approach. Recurrence is not expected in general. However, cases of recurrence after a long period of time have also been reported. In this study, a 46-year-old female patient was presented with thyroid inflammatory myofibroblastic tumor that developed after COVID-19. Another notable point in the case is that her mother had myeloma with mutations (changes in chromosomes 11 and 14).

关 键 词：Inflammatory Myofibroblastic TUMOR THYROID ALK 

分 类 号：R73[医药卫生—肿瘤]